Safely Skip PET2 After Brentuximab in Hodgkin Lymphoma? Safely Skip PET2 After Brentuximab in Hodgkin Lymphoma?
Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job.
Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.
[time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news
High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody
(MedPage Today) -- HOUSTON -- More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a pivotal trial.
Overall... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2023 Category: Hematology Source Type: news
Study Questions Value of Interim PET Imaging to Guide Frontline Hodgkin Treatment
(MedPage Today) -- HOUSTON -- Interim PET-CT imaging (PET2) had almost no impact on clinical decision-making for Hodgkin lymphoma treated with brentuximab vedotin (Adcetris), according to a small clinical study reported here.
One of 40 patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 9, 2023 Category: Hematology Source Type: news
Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies
(MedPage Today) -- Use of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) for patients with aggressive lymphoma was associated with an increased risk of certain second primary malignancies (SPMs), according... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 9, 2023 Category: Hematology Source Type: news
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Resubmission to FDA planned for early 2024
CRANFORD, N.J., Sept. 8, 2023 -- (Healthcare Sales & Marketing Network) -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has rec... Biopharmaceuticals, Oncology, FDA Citius Pharmaceuticals, LYMPHIR, denileukin diftitox, T-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2023 Category: Pharmaceuticals Source Type: news
PET reveals link between heart health and brain metabolism
A PET study suggests that maintaining cardiovascular health during midlife ca...Read more on AuntMinnie.comRelated Reading:
PET/CT scans predict CAR-T therapy response in lymphoma patients
PET shows promise in diagnosing atypical parkinsonism
AI outperforms clinical scores in high-risk lymphoma patients
PET/CT links stress and poor outcomes in cancer patients
PET confirms efficacy of first-line cardiac sarcoidosis treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 7, 2023 Category: Radiology Source Type: news
I was diagnosed with terminal non-Hodgkin's lymphoma cancer aged 20 despite being in peak physical condition - I mistook my symptoms as burnout
Lee Troutman, from Georgia, was diagnosed with late-stage lymphoma last year after suffering from night sweats, fatigue, and liver pain. Before diagnosis, he had worked out 12 hours a day. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2023 Category: Consumer Health News Source Type: news
Roche & #039;s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Phase III ALINA study evaluating Alecensa® (alectinib), compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival (DFS) at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - September 6, 2023 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Response: Alternative approaches for systematic review - Goodman JE, Ticknor RC, Zhou J.
We appreciate the opportunity to respond to the commentaries on our paper, "Systematic Review of Perchloroethylene and Non Hodgkin's Lymphoma." [1] As noted by LaKind et al. [2], there are an overwhelming number of systematic review frameworks, many of whi... (Source: SafetyLit)
Source: SafetyLit - September 1, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Media News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Investor Update - September 1, 2023 Category: Pharmaceuticals Source Type: news
FDG-PET/CT scan reveals rare neurosarcoidosis
An FDG-PET/CT scan and thyroid biopsy changed a patient's diagnosis from termina...Read more on AuntMinnie.comRelated Reading:
Are PSMA-PET tracers equal in detecting prostate cancer?
PET/CT scans predict CAR-T therapy response in lymphoma patients
AI outperforms clinical scores in high-risk lymphoma patients
PET/CT links stress and poor outcomes in cancer patients
PET/CT improves survival outcomes in patients with HNSCC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 30, 2023 Category: Radiology Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
